Novo Nordisk's Two-Sided Week: A Legal Win and a Raised Outlook, Yet the Market Demands More
Published on 08/06/2026 at 22:21 | Redaktion boerse-global.de
The arithmetic of investor trust rarely follows a straight line, and Novo Nordisk's latest chapter proves the point. The Danish pharma giant delivered a second-quarter report that, on the surface, pointed toward stabilization — higher sales, faster profit growth, and an upgraded full-year outlook. The market's response was anything but forgiving.
Shares in Copenhagen slid as much as 7.1 percent on Wednesday, according to Reuters, before paring losses. By Thursday, the stock had clawed back some ground, trading at 39.78 euros in Frankfurt with a 2.75 percent gain, while the Copenhagen listing hovered near 39.25 euros, up 1.38 percent on the day. Those partial recoveries do little to mask the damage: the stock remains roughly 1.28 percent below its 200-day moving average and has shed nearly 11 percent over the past week, leaving it far adrift of its 52-week high of 54.86 euros.
A Forecast Upgrade That Failed to Sway
The operational numbers told a story of quiet resilience. Adjusted operating profit rose 11 percent on a currency-adjusted basis to 33.389 billion Danish kroner in the second quarter of 2026, while adjusted revenue climbed 7 percent to 78.488 billion kroner. Management narrowed its full-year guidance to a range of flat to minus 6 percent growth for both revenue and operating profit, a marked improvement from the previous projection of a 4 to 12 percent decline.
That upgrade, however, landed below what investors had hoped to hear. The market's skepticism was compounded by a non-cash impairment charge of 6.3 billion kroner against intangible pipeline assets, with 4.0 billion kroner tied to the drug candidate monlunabant alone. Saxo Bank noted that options pricing ahead of the August 5 results release had implied a move of roughly 8 percent — the actual reaction came close to matching that, underscoring how finely balanced sentiment had become.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The Pill Problem
Perhaps the more telling disappointment came from the oral Wegovy pill. Sales of the tablet form met market expectations but failed to exceed them, and in a stock priced for outperformance, meeting the bar was not enough. Jefferies analyst Michael Leuchten told Reuters on Thursday that the quarter and the subdued pill sales relative to lofty expectations left "many questions open" about the company's competitiveness heading into 2027.
Morningstar's Karen Andersen took action on the same day, trimming her fair value estimate for the shares from 311 to 285 Danish kroner, citing lower long-term gross margin assumptions and reduced sales expectations for CagriSema following lackluster clinical results. The analyst's move reflects a broader reassessment: the pipeline setbacks of recent months have chipped away at the growth narrative that once commanded a premium valuation.
A Legal Shield for Semaglutide
Amid the financial turbulence, Novo Nordisk secured a meaningful legal victory. A court in The Hague issued a preliminary injunction against Dutch pharmacy Ceban Ziekenhuisfarmacie, barring it from selling "Semanova," a self-compounded semaglutide nasal spray. The court found the product infringed Novo Nordisk's Dutch supplementary protection certificate SPC 300936, which remains in force until 2031. The ruling bolsters the company's pricing power against cheaper compounded imitations, a growing competitive threat across European markets.
Pipeline: Mixed Signals
The clinical picture is more nuanced than the share price suggests. In late July, the Phase 3 ZEUS trial of ziltivekimab in patients with atherosclerotic cardiovascular disease and chronic kidney disease missed its primary endpoint — a setback for the company's push into cardiovascular indications. Yet early August brought a more positive readout: the same drug candidate significantly reduced the risk of major cardiovascular events in that patient population. The conflicting signals illustrate the uneven progress of a pipeline in transition.
The company is also pressing ahead with commercial expansion. Germany is set to become the first EU market to launch the oral Wegovy pill in September 2026, following European Commission approval in July. The launch will serve as a critical test of whether the oral formulation can expand the patient base or merely cannibalize existing Wegovy users — a distinction that could shape the growth debate for quarters to come.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Support Beneath the Surface
Several factors provide a floor under the stock. CEO Mike Doustdar told analysts on the earnings call that the company would accelerate research and development spending to rebuild a pipeline weakened by failed studies. The buyback program continues apace: since the start of the current tranche, Novo Nordisk has repurchased 27,064,179 B-shares for 7.53 billion kroner as of August 3, within a 15 billion kroner twelve-month program. A dividend of 0.5786 US dollars per share remains payable on August 25.
The tension is plain: operational discipline and legal protections on one side, pipeline disappointments and demanding expectations on the other. The September launch of the oral pill in Germany will offer the next concrete read on whether Novo Nordisk can rebuild the confidence that has eroded so visibly over recent weeks. Until then, the stock looks set to remain hostage to a market that has made clear that incremental improvements no longer suffice.
Ad
Novo Nordisk Stock: New Analysis - 6 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
